Provexis plc (AIM: PXS)

Market Cap	14.71M
Revenue (ttm)	801.96K
Net Income (ttm)	-586.24K
Shares Out	2.26B
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,830,000
Open	0.600
Previous Close	0.650
Day's Range	0.600 - 0.690
52-Week Range	0.450 - 0.900
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 10, 2024

About Provexis

Provexis plc, together with its subsidiaries, develops, licenses, and sells functional foods, medical foods, and dietary supplements worldwide. The company offers syrup and powder versions of Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke used in various foods, beverages, and dietary supplement formats. It also provides Fruitflow+ Omega-3, a dietary supplement product. The company sells its products through company’s website a...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1999
• Employees: 2
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: PXS

Financial Performance

In 2023, Provexis's revenue was 801,964, an increase of 105.68% compared to the previous year's 389,916. Losses were -586,243, 52.2% more than in 2022.